InvestorPlace - Stock Market News, Stock Advice & Trading Tips
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
The post URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace.
More From InvestorPlace